As post-tamoxifen therapy, letrozole cuts breast cancer recurrence 43%

Article

Letrozole therapy, in follow-up to 5 years of tamoxifen treatment, significantly improves disease-free survival compared to placebo, according to a study published in The New England Journal of Medicine.

Related Content
FDA Approves First Nonprescription Oral Contraceptive

FDA Approves First Nonprescription Oral Contraceptive

July 13th 2023
Article

Opill will be available in stores and online in the first quarter of 2024.

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

March 29th 2023
Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

FDA Approves Second Indication for Brexafemme

FDA Approves Second Indication for Brexafemme

December 2nd 2022
Article

Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.

FDA Approves Liletta IUD to Prevent Pregnancy for 8 Years

FDA Approves Liletta IUD to Prevent Pregnancy for 8 Years

November 14th 2022
Article

The approval extends the use of Liletta for an additional two years. It is the only hormonal IUD approved for continuous use up to eight years.

Real-world Data Show Gardasil Protects Against Cervical, Non-Cervical Diseases

Real-world Data Show Gardasil Protects Against Cervical, Non-Cervical Diseases

November 7th 2022
Article

The greatest reductions were seen in girls who were vaccinated when they were adolescents, with up to 73% reduction in cervical pre-cancerous lesions.

FDA Postpones Advisory Committee Meeting for OTC Birth Control

FDA Postpones Advisory Committee Meeting for OTC Birth Control

October 27th 2022
Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact